Skip to main content
Fig. 2 | Journal of Neurodevelopmental Disorders

Fig. 2

From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Fig. 2

Flow diagram of participants in the CONNECT-FX trial. a indicates the following: failure to meet randomization criteria. b indicates the following: received at least one dose of double-blind treatment. c indicates the following: all patients in the safety analysis set with both a baseline and at least one post-baseline efficacy measurement

Back to article page

Journal of Neurodevelopmental Disorders

ISSN: 1866-1955

Contact us